Azar Jehad, Ayyad Mohammed, Jaber Yasmin, Ayasa Laith Azzam
Pulmonary and Critical Care Department, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Internal Medicine Department, Al Quds University, Abu Dis, State of Palestine.
BMJ Case Rep. 2023 Apr 3;16(4):e254730. doi: 10.1136/bcr-2023-254730.
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that results in precapillary pulmonary hypertension. PAH is caused by a group of clinical conditions involving multiple organ systems. Several cases have been reported in the literature demonstrating an association between vitamin C deficiency and PAH. Low endothelial nitric oxide levels in the pulmonary vasculature, combined with the inappropriate activation of hypoxia-inducible transcription factors, seen in patients with ascorbic acid deficiency, are believed to be the main contributors to the pathogenesis of pulmonary vasculopathy and the exaggerated pulmonary vasoconstrictive response seen in patients with scurvy-induced PAH. Vitamin C supplementation is considered the definitive treatment.
肺动脉高压(PAH)是一种肺血管的进行性疾病,可导致毛细血管前肺动脉高压。PAH由一组涉及多个器官系统的临床病症引起。文献中已报道了几例病例,表明维生素C缺乏与PAH之间存在关联。肺血管中内皮一氧化氮水平低,再加上在抗坏血酸缺乏患者中可见的缺氧诱导转录因子的不适当激活,被认为是肺血管病变发病机制以及坏血病诱导的PAH患者中出现的过度肺血管收缩反应的主要促成因素。补充维生素C被认为是决定性的治疗方法。